Back to Search
Start Over
Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity.
- Source :
-
Pediatrics [Pediatrics] 2018 May; Vol. 141 (5). Date of Electronic Publication: 2018 Apr 11. - Publication Year :
- 2018
-
Abstract
- Background and Objectives: Caffeine is effective in the treatment of apnea of prematurity. Although caffeine therapy has a benefit on gross motor skills in school-aged children, effects on neurobehavioral outcomes are not fully understood. We aimed to investigate effects of neonatal caffeine therapy in very low birth weight (500-1250 g) infants on neurobehavioral outcomes in 11-year-old participants of the Caffeine for Apnea of Prematurity trial.<br />Methods: Thirteen academic hospitals in Canada, Australia, Great Britain, and Sweden participated in this part of the 11-year follow-up of the double-blind, randomized, placebo-controlled trial. Measures of general intelligence, attention, executive function, visuomotor integration and perception, and behavior were obtained in up to 870 children. The effects of caffeine therapy were assessed by using regression models.<br />Results: Neurobehavioral outcomes were generally similar for both the caffeine and placebo group. The caffeine group performed better than the placebo group in fine motor coordination (mean difference [MD] = 2.9; 95% confidence interval [CI]: 0.7 to 5.1; P = .01), visuomotor integration (MD = 1.8; 95% CI: 0.0 to 3.7; P < .05), visual perception (MD = 2.0; 95% CI: 0.3 to 3.8; P = .02), and visuospatial organization (MD = 1.2; 95% CI: 0.4 to 2.0; P = .003).<br />Conclusions: Neonatal caffeine therapy for apnea of prematurity improved visuomotor, visuoperceptual, and visuospatial abilities at age 11 years. General intelligence, attention, and behavior were not adversely affected by caffeine, which highlights the long-term safety of caffeine therapy for apnea of prematurity in very low birth weight neonates.<br />Competing Interests: POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.<br /> (Copyright © 2018 by the American Academy of Pediatrics.)
- Subjects :
- Apnea drug therapy
Apnea etiology
Child
Double-Blind Method
Female
Follow-Up Studies
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases drug therapy
Infant, Very Low Birth Weight
Male
Motor Skills drug effects
Caffeine therapeutic use
Central Nervous System Stimulants therapeutic use
Child Development
Psychomotor Performance drug effects
Spatial Processing drug effects
Visual Perception drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1098-4275
- Volume :
- 141
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Pediatrics
- Publication Type :
- Academic Journal
- Accession number :
- 29643070
- Full Text :
- https://doi.org/10.1542/peds.2017-4047